Nama's AI scorecard currently rates Beam Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does BEAM report earnings?

Beam Therapeutics's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$1.29.

What is the BEAM price target?

The median analyst price target from 13 analysts is $44.00, with a range of $26.00 – $80.00.

Is BEAM Shariah compliant?

Nama's AAOIFI-style screen reads Beam Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Beam Therapeutics (BEAM)

Healthcare · Biotechnology · NASDAQ

Beam Therapeutics (BEAM) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.73B and a free-cash-flow yield of -13.8%. Over the most recent reported fiscal year, revenue grew 120.0%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +7.0% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-73.6%

How far the last close sits under the highest price of the past five years.

Market cap	$2.73B
Trailing P/E	—
Price / book	2.5
Price / sales	17.5
FCF yield	-13.8%
Dividend yield	—
Gross margin	-161.9%
Operating margin	-25827.1%
Net margin	-55.5%
Revenue growth (YoY)	+120.0%
Revenue growth (3-yr annual)	+31.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

BEAM earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$1.29). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	-$1.28	-$1.17	-9.4%	$307,000
Q2 2026	Aug 4, 2026	-$1.18	-$1.13	-4.4%	$490,000
Q1 2026	May 7, 2026	-$0.91	-$1.01	+9.9%	$31.74M
Q4 2025	Feb 24, 2026	$2.33	-$1.12	+308.0%	$114.11M

BEAM analyst price target

Median target $44.00 from 13 analysts, ranging $26.00 – $80.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live BEAM data on Nama Insights →

BEAM FAQ

Is BEAM a buy?: Nama's AI scorecard currently rates Beam Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does BEAM report earnings?: Beam Therapeutics's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$1.29.
What is the BEAM price target?: The median analyst price target from 13 analysts is $44.00, with a range of $26.00 – $80.00.
Is BEAM Shariah compliant?: Nama's AAOIFI-style screen reads Beam Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.